Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A. Canal P, et al. Among authors: mathieu boue a. J Clin Oncol. 1996 Oct;14(10):2688-95. doi: 10.1200/JCO.1996.14.10.2688. J Clin Oncol. 1996. PMID: 8874328 Clinical Trial.
CPT-11-induced cholinergic effects in cancer patients.
Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P. Gandia D, et al. J Clin Oncol. 1993 Jan;11(1):196-7. doi: 10.1200/JCO.1993.11.1.196. J Clin Oncol. 1993. PMID: 8418235 No abstract available.
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M. Catimel G, et al. Among authors: mathieu boue a. Ann Oncol. 1995 Feb;6(2):133-40. doi: 10.1093/oxfordjournals.annonc.a059108. Ann Oncol. 1995. PMID: 7786821 Free article. Clinical Trial.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué A, Houghton JA. Houghton PJ, et al. Cancer Res. 1993 Jun 15;53(12):2823-9. Cancer Res. 1993. PMID: 8504425
17 results